Saratov JOURNAL of Medical and Scientific Research

An additional criterion for assessing the neovascular membrane activity in the wet form of age-related macular degeneration

Year: 2021, volume 17 Issue: №3 Pages: 649-652
Heading: Тhematic supplement Article type: Original article
Authors: Kolbenev I.O., Kamenskikh T.G., Zaretskova T.М.
Organization: Saratov State Medical University, University Clinical Hospital №2 (Clinic of Eye Diseases)
Summary:

Purpose: to develop an additional criterion for assessing the neovascular membrane activity in order to provide a more balanced approach to the appointment of angiogenesis inhibitors in the treatment of wet neovascular age-related macular degeneration (nAMD). Material and Methods. Sixty-one patients (61 eyes) with nAMD were examined. The average age is 69±7 years. Two groups were formed: The 1st group included 35 patients (35 eyes) with an active neovascular membrane; the 2nd group consisted of 26 patients (26 eyes) with an inactive neovascular membrane. All patients underwent optical coherence tomography using a REVO NX apparatus. Results, как отношение площади новообразованных сосудов, занимающих выделенную область неоваскулярной мембраны, к площади самой неоваскулярной мембраны The coefficient as the ratio of the area of newly formed vessels, which occupy the selected domain of the neovascular membrane, to the area of the neovascular membrane itself (F/V) has been developed. When comparing the average values of the F/V ratio in the 1st and 2nd groups, significant differences were obtained (p=0.01). In the absence of neovascular membrane activity, the value of this indicator significantly increased (p=0.01). Conclusion. The obtained coefficient can be considered an additional criterion for assessing the neovascular membrane activity.

Bibliography:
1. Ferrara N, Davis-Smyth T. The Biology of Vascular Endothelial Growth Factor. Endocrine Reviews 1997; 18 (1): 4-25.
2. Pierce EA,Avery RL, Foley ED, etal. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci USA 1995;92:905-9.
3. Roberts WG, Palade G. Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J Cell Sci 1995; 108: 2369-79.
4. Budzinskaya MV, Vorobyova MV, Kiseleva TN, et al. Modern approaches to treatment and prophylaxis of age related macular degeneration. Clinical Ophthalmology 2007; 8 (2): 78-82.
5. Egorov ЕА, Romanenko IA. Age-related macular degeneration: questions of pathogenesis, diagnostics and treatment. RMJ Clinical Ophthalmology 2009; 1: 42.
6. Fayzrakhmanov RR. Anti-VEGF therapy of neovascular age-related macular degeneration: from randomized trials to routine clinical practice. Russian Ophthalmological Journal 2019; 12 (2): 97-105.
7. Egorov ЕА, Romanenko IA, Romanova ТВ, et al. Ranibizumab (Lucentis) in treatment of patients with wet type of age-related macular degeneration. RMJ Clinical Ophthalmology 2010; 2: 65.
8. Kasimov ЕМ, Shakhmaliyeva AM, Gadzhiyeva ВН. On the efficiency of treatment of wet age-related macular degeneration with Lucentis. Russian Ophthalmological Journal. 2016; 9 (2): 33-7.
9. Shaimov ТВ, Panova IE, Shaimov RB, et al. Optical coherence tomography angiography in the diagnosis of neovascular age-related macular degeneration. Bulletin of Ophthalmology 2015; 5: 10-1.
10. Kamenskikh TG. A differentiated approach to analysis of retinal fluid and assessment of its effect on anti-VEGF therapy of neovascular age-related macular degeneration. Bulletin of Ophthalmology 2019; 135 (6): 134-40.

AttachmentSize
2021_03-2_649-652.pdf1.08 MB

No votes yet